The fundamental principles of the Creighton Model FertilityCare System (CrMS) have been known to physicians for many years and well documented, but unfortunately, almost completely disregarded by physicians. In 1952, Cohen, et. Al, observed the changes in cervical mucus as ovulation approaches. It was noted that as ovulation approaches the stretchability, clarity, and production of cervical mucus increases, and the viscosity of the mucus decreases. The most important discovery was that the survival of spermatozoa directly correlates with the quality and presents or absence of this cervical mucus prior to ovulation.
In the CrMS, external observations of the vulvar area for cervical mucus, the days of bleeding, and the days where this mucus is absent, are all used to determine the state of fertility and
infertility from day to day, as well as the state of the woman's procreative and gynecological health.
This allows the couple to decide for themselves, based on the fertility of the day, whether they want to use the system to avoid a pregnancy or achieve a pregnancy. And for the first time a woman can monitor her reproductive and gynecological health. From the CrMS the new women's health science of NaProTechnology was born. After many years of extensive research, these biomarkers have been shown to reveal the presence or absence of pathological and physiological abnormalities. The client(s), their Practitioner and a trained Medical consultant work as a team to detect any health issues so that health can be restored for the woman. The chart itself serves as both a medical record documenting these biomarkers, and a guide for the effective timing of any medical tests and/or procedures.